These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 6818930)

  • 61. Current status of Pseudomonas aeruginosa vaccine.
    Michelim L; Medeiros GS; Zavascki AP
    Curr Pharm Biotechnol; 2013; 14(11):951-9. PubMed ID: 24372247
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Chemotherapy of infections caused by Pseudomonas aeruginosa (pyocyanosis)].
    Chernomordik AB; Panchenko MK; Bulycheva NP
    Klin Med (Mosk); 1982 Jun; 60(6):17-20. PubMed ID: 6811797
    [No Abstract]   [Full Text] [Related]  

  • 63. Clinical surveillance of surgical imipenem-resistant Pseudomonas aeruginosa infection in a Japanese hospital.
    Sasaki M; Hiyama E; Takesue Y; Kodaira M; Sueda T; Yokoyama T
    J Hosp Infect; 2004 Feb; 56(2):111-8. PubMed ID: 15019222
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Urinary tract infection caused by Pseudomonas aeruginosa].
    Shiraiwa Y; Ishibashi K
    Nihon Rinsho; 1991 Oct; 49(10):2399-404. PubMed ID: 1749096
    [No Abstract]   [Full Text] [Related]  

  • 65. [Mechanisms of resistance in Pseudomonas aeruginosa].
    Cercenado Mansilla E; García Garrote F
    Rev Clin Esp; 1998 Sep; 198 Suppl 2():10-6. PubMed ID: 9844472
    [No Abstract]   [Full Text] [Related]  

  • 66. [Donor plasma with anti-Pseudomonas aeruginosa activity as a directed-action preparation].
    Nazarchuk LV
    Vrach Delo; 1987 Jul; (7):96-8. PubMed ID: 3114958
    [No Abstract]   [Full Text] [Related]  

  • 67. [Dependence of immunological reactivity on blood groups and microflora in patients with chronic purulent otitis media].
    Zemskov AM; Poliakova SD
    Vestn Otorinolaringol; 1996; (5):39-42. PubMed ID: 8999648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients.
    Falagas ME; Rafailidis PI; Matthaiou DK; Virtzili S; Nikita D; Michalopoulos A
    Int J Antimicrob Agents; 2008 Nov; 32(5):450-4. PubMed ID: 18768302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Control of Pseudomonas aeruginosa infections.
    Klastersky J
    Acta Clin Belg; 1974; 29(4):233-9. PubMed ID: 4215269
    [No Abstract]   [Full Text] [Related]  

  • 70. Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan.
    Hsueh PR; Tseng SP; Teng LJ; Ho SW
    Clin Microbiol Infect; 2005 Aug; 11(8):670-3. PubMed ID: 16008621
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Comparative study of the effect of sisomicin and other aminoglycosides on the causative agents of surgical infection].
    Navashin PS
    Antibiotiki; 1982 Dec; 27(12):26-9. PubMed ID: 6819812
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
    Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C
    J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
    Prasad SV; Ballal M; Shivananda PG
    Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods.
    Pressler T; Karpati F; Granström M; Knudsen PK; Lindblad A; Hjelte L; Olesen HV; Meyer P; Høiby N;
    J Cyst Fibros; 2009 Jan; 8(1):37-42. PubMed ID: 18835753
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence and antimicrobial susceptibility of Pseudomonas aeruginosa mucoid and non-mucoid type.
    Srifuengfung S; Tiensasitorn C; Yungyuen T; Dhiraputra C
    Southeast Asian J Trop Med Public Health; 2004 Dec; 35(4):893-6. PubMed ID: 15916087
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Live, attenuated vaccines against Pseudomonas: observations in the experimental animal and the human.
    Bellanti JA; Sordelli DO; Cerquetti MC; Wan KS; Arias G; Cereb N; Zuba D; Kulczycki L; Hooke AM
    Ann Sclavo Collana Monogr; 1986; 3(1-2):247-58. PubMed ID: 3122803
    [No Abstract]   [Full Text] [Related]  

  • 77. Report: prevalence and resistance pattern of Pseudomonas aeruginosa against various antibiotics.
    Khan JA; Iqbal Z; Rahman SU; Farzana K; Khan A
    Pak J Pharm Sci; 2008 Jul; 21(3):311-5. PubMed ID: 18614431
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Value of orbicin iv infusions in severe surgical infections. Serum level and clinical effect].
    Moorthi K; Ghobadi M; Schroer H
    Med Welt; 1980 Aug; 31(34):1209-10. PubMed ID: 6776380
    [No Abstract]   [Full Text] [Related]  

  • 79. A Pseudomonas aeruginosa isolate producing the GES-5 extended-spectrum beta-lactamase.
    Wang C; Cai P; Chang D; Mi Z
    J Antimicrob Chemother; 2006 Jun; 57(6):1261-2. PubMed ID: 16617065
    [No Abstract]   [Full Text] [Related]  

  • 80. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
    Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
    J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.